Regenerative Medicine
Diabetes: Medtronic joins $44m round for Semma Therapeutics
InVivo Therapeutics readies reverse split ahead of NASDAQ listing
InVivo Therapeutics reports narrowed 2014 losses
(OTC:IVOB) reported a narrowed annual loss, due in part to changes in the market value of the company’s derivative warrant liability.
TEI, Novation sign contract for biologic mesh products
Regenerative medicine company TEI Biosciences said that it has been awarded a supply contract by group purchasing organization Novation for its biologic mesh products.
Osiris strikes deal with Stryker for bone-repair product
FDA OKs expedited enrollment for InVivo study
EU’s top court opens door to some stem cell patents
Xeltis raises $34m for regenerative heart valve tech
Histogenics sets range for $60m IPO
Histogenics set the per-share price range on its forthcoming initial public offering at $13 to $15 per share.
That puts the mid-point for the nearly 4.3 million-share offering at just under $60 million.